Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
about
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancerIdentification of potent EGFR inhibitors from TCM Database@TaiwanQSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFRFrom oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.The quest to overcome resistance to EGFR-targeted therapies in cancer.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesTargeting the EGFR signaling pathway in cancer therapy.Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceA phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa").hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.Resistance to Therapy.Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway.Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.Oxidative dehydrogenation of C-C and C-N bonds: A convenient approach to access diverse (dihydro)heteroaromatic compounds.Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas.Gefitinib: a consideration of cost.Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.Facile Preparation of 4-Substituted Quinazoline Derivatives.
P2860
Q21198843-972D78C0-AC6F-4F5E-8844-00954B2C3BC4Q28477481-505CC309-D382-4DA0-9096-54759019BF82Q28540324-F174724C-D397-4CCE-AF7F-A019235A282CQ30168082-FB760B73-D6F0-4B01-8137-23EC1DEF2BCFQ33725976-84C52C73-E41C-4E77-BA56-7B3C7A69A81CQ34088424-DC8C226E-0A4D-421C-B358-7D3215EC5C5AQ34246558-A018EE00-91AC-4B20-9692-AC0EC778D09EQ36181201-9F09D5D1-291A-469D-ADBB-0D9A7487DD2FQ36250585-D7E51205-6BB5-408F-857B-5D430300F6CDQ36614353-E12906B3-BDDD-4021-A0D4-D7B4372FC367Q36643855-7D7A013E-F0A4-4E0A-899A-6CA5F615ABC4Q38304521-0A5BD5CC-B8B4-4523-8AE6-D02BBDB24755Q38798293-2E478FC4-FA83-41B8-A5D5-0D4B6F8C7F54Q38930367-D662AB55-DB8E-4E99-A066-E86D4065F19DQ39559565-E4DA64B4-177D-44CF-AC41-A85310E35D47Q40732059-B918E70F-CA4D-45EF-A9B5-EA89A7778B48Q40781423-B50DB6FD-09EE-4724-ABD5-4AFF7B7AB12DQ41469033-58619BAE-CABD-4C07-999D-0640D3E718F9Q42835389-567263A4-9544-45EA-B815-41CECE53A180Q43042819-D50096AA-9EBC-4762-A1B5-26B6A19BA660Q43981261-79664DBE-D4F1-4EC3-8493-50EB6E9286ECQ49611544-086DD8A6-1EF9-44D7-A45A-07446BC5D20CQ51450871-AEA8E295-E0A2-4AF0-A904-829EFE7FA1E0
P2860
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Specific inhibition of epiderm ...... nase by 4-anilinoquinazolines.
@en
type
label
Specific inhibition of epiderm ...... nase by 4-anilinoquinazolines.
@en
prefLabel
Specific inhibition of epiderm ...... nase by 4-anilinoquinazolines.
@en
P2093
P356
P1476
Specific inhibition of epiderm ...... nase by 4-anilinoquinazolines.
@en
P2093
Cartlidge SA
Wakeling AE
Woodburn JR
P2888
P356
10.1007/BF01803785
P407
P577
1996-01-01T00:00:00Z